Buy ADB-FUBINACA 10g
Buy ADB-FUBINACA 10g is a designer drug identified in synthetic cannabis blends in Japan in 2013.
The (S) enantiomer of ADB FUBINACA 10g is claimed in Pfizer patent WO 2009/106982 and has been reported to be a potent agonist of the CB1 receptor and CB2 receptor with an EC50 value of 1.2 nM and 3.5 nM respectively.
ADB FUBINACA features a carboxamide group at the 3-indazole position, like SDB-001 and STS-135.
ADB FUBINACA appears to be the product of rational drug design, since it differs from AB-FUBINACA only by the replacement of the isopropyl group with a tert-butyl group.
An analogue of ADB-FUBINACA, ADSB-FUB-187, containing a more functionalized carboxamide substituent was recently reported.
ADB-FUBINACA SIDE EFFECTS
One death through coronary arterial thrombosis has been linked to ADB FUBINACA intoxication.
At least an additional 8 deaths in Hungary in 2015 are linked to the usage of this material, all deaths were younsgters below 21.
Twenty-three ADB-FUBINACA major metabolites were identified in several incubations with cryopreserved human hepatocytes.
Major metabolic pathways were alkyl and indazole hydroxylation, terminal amide hydrolysis, subsequent glucuronide conjugations, and dehydrogenation.